X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Nkarta intends to use the net proceeds to fund the continued research and clinical development of NKX019, a cryopreserved, allogeneic CD19-targeting CAR NK-cell therapy, being developed for relapsed/refractory non-Hodgkin lymphoma.
Lead Product(s): NKX019
Therapeutic Area: Oncology Product Name: NKX019
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Adage Capital Partners LP
Deal Size: $240.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 25, 2024
Details:
NKX019 is an allogeneic, cryopreserved, off-the-shelf immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy adult donors, which is investigated for the treatment of Lupus Nephritis.
Lead Product(s): NKX019
Therapeutic Area: Nephrology Product Name: NKX019
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2023
Details:
NKX101 is an allogeneic, off-the-shelf cell therapy candidate comprising NK cells derived from healthy donors and engineered to target NKG2D ligands on cancer cells and is being investigated for Relapsed or Refractory Acute Myeloid Leukemia.
Lead Product(s): NKX101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: NKX101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
NKX019 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses NK cells engineered to target the B-cell antigen CD19, a clinically validated target for B-cell cancer therapies.
Lead Product(s): NKX019,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: NKX019
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
NKX101 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy donors.
Lead Product(s): NKX101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: NKX101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
Nkarta intends to use the net proceeds from the offering to fund the continued clinical development of NKX101 and NKX019, preclinical studies for research stage programs.
Lead Product(s): NKX101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: NKX101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cowen
Deal Size: $230.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 28, 2022
Details:
Nkarta intends to use the net proceeds to fund the continued clinical development of NKX101 and NKX019, preclinical studies for research stage programs and the continued buildout of internal manufacturing capabilities, and for working capital and general corporate purposes.
Lead Product(s): NKX101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: NKX101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cowen
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 26, 2022
Details:
Nkarta intends to use the net proceeds from the offering to fund the continued clinical development of NKX101 and NKX019, preclinical studies for research stage programs and the continued buildout of internal manufacturing capabilities.
Lead Product(s): NKX101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: NKX101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cowen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering April 25, 2022
Details:
NKX101 – 3 of 5 patients with relapsed / refractory AML treated with a three-dose regimen consisting of 1B or 1.5B CAR NK cells per dose achieved complete response with full hematologic recovery (60% CR rate); 2 of 3 CRs are MRD negative.
Lead Product(s): NKX101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: NKX101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
NKX101,is a healthy donor-derived CAR-NK investigational therapy targeting NKG2D ligands on tumor cells, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes.
Lead Product(s): NKX101,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: NKX101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
